Japanese pharmaceutical company Eisai Co. Ltd. (ESALF.PK), a partner of BioArctic AB (publ) (BRCTF.PK), Friday announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has reaffirmed its positive opinion for lecanemab for the treatment of early Alzheimer's disease.
Following this, the European Commission will resume the decision-making process for lecanemab's marketing authorisation.
Earlier this year, the Commission has asked CHMP to re-evaluate its information on safety of lecanemab, and check whether it requires an update to its previous opinion about the product.
If the Commission approves the marketing authorization application, lecanemab would be available in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.